SAN DIEGO, CA — There is a need for new, effective treatments for mental illnesses like depression and anxiety. Researchers are expanding the field’s therapeutic toolbox by investigating the antidepressant and anxiolytic properties of drugs such as psilocybin and cannabis. The findings were presented at Neuroscience 2022, the annual meeting of the Society for Neuroscience and the world’s largest source of emerging news about brain science and health.
Mood disorders are among the most frequently diagnosed mental illnesses worldwide. Current drug treatments for these disorders, such as serotonin modulators and benzodiazepines, are slow to take effect, and when they do, they often bestow unwanted side effects. Additionally, many people with depression don’t respond at all to these medications. However, treatments derived from the psychedelic compound psilocybin and the psychoactive drug cannabis may be promising for a range of mental health disorders. Neuroscientists are probing how they work in the brain.
Today’s new findings show that:
“As a field, we are thinking about psilocybin and cannabis in new ways and not only evaluating them for their potential therapeutic benefit but probing how they exert their effects in the brain,” says Lisa Monteggia, the Barlow Family Director of the Vanderbilt Brain Institute and professor pharmacology at Vanderbilt University, who studies mechanisms underlying antidepressant efficacy. “The research presented today is contributing to the growing evidence that these compounds may offer new avenues for symptom relief in many mental health conditions.”
This research was supported by national funding agencies including the National Institutes of Health and private funding organizations. Find out more about social behavior and the brain on BrainFacts.org.
Press Conference Summary
- Many people who take conventional drug treatments do not experience symptom relief.
- Researchers are investigating compounds such as psilocybin and cannabis to better understand how they produce anti-depressive and anti-anxiety effects.
Investigating Altered Consciousness and the Role of Serotonin Receptors in the Therapeutic Effects and Mechanisms of Actions of Psilocybin
Katherine M. Nautiyal, katherine.nautiyal@dartmouth.edu, Abstract 229.05
Inhibition of Fatty Acid Binding Protein-5 Stress-Induced Anxiety-Like and Depression-Like Psychopathology
Steven R. Laviolette, steven.laviolette@schulich.uwo.ca, Abstract 400.07
Normalization of Goal-Directed Behaviors Associated With Chronic Cannabis Use in Bipolar Disorder
Alannah Miranda, ahmirand@health.ucsd.edu, Abstract 562.06